Ambry Genetics, a provider of clinical diagnostic testing, and Tempus, which offers AI and precision medicine solutions, have entered into a strategic collaboration to offer comprehensive germline and somatic testing services.

As part of the agreement, Ambry is performing germline sequencing assays for Tempus, powered by Ambry’s CancerNext and CancerNext-Expanded assays. Utilizing next-generation sequencing, the assays identify genetic variants associated with hereditary cancer syndromes and inherited risk of cancer, and leverage Ambry’s 25-year history of variant interpretation expertise, the companies said. 

“We aim to be a one-stop-shop for clinicians as they navigate each patient’s treatment path, and germline testing is a critical element in diagnosing and treating patients that may have existing hereditary mutations,” says Mike Yasiejko, executive vice president and general manager, Genomics at Tempus. “Ambry has extensive experience in germline genetic testing, and we look forward to working together to enhance our molecular profiling offerings.”

Further reading: Personalis and Tempus Collaborate to Advance Cancer Testing

Tempus’ xG and xG+ germline assays are a part of Tempus’ portfolio of oncology-focused testing solutions that maximize biomarker detection and identify actionable variants linked to targeted therapy and clinical trial options. Tempus offers a collection of genomic profiling solutions of solid tumor and liquid biopsy, along with algorithmic-based tests such as HRD and TO (tumor of unknown origin). These tools are designed to help physicians optimize patient care by providing clinically actionable data that can inform decisions throughout the treatment journey. 

“Our collaboration with Tempus will provide an invaluable resource for patients and physicians because it leverages our respective expertise,” says Brigette Tippin Davis, PhD, chief operating officer of Ambry Genetics. “Tempus has a powerful offering for tissue and liquid biopsy DNA and RNA profiling and somatic testing. Now, with our germline testing and variant assessment expertise behind Tempus xG and xG+, we are poised to create a future where paired somatic and germline testing is the standard. We believe this will drive precision oncology, proactive healthcare for those patients at hereditary risk, and insights that may affect generations.”

Featured image: Ambry Headquarters. Photo: Ambry